Eisai President Warns Other Industries About Pharma M&A Risks
This article was originally published in PharmAsia News
Executive Summary
Commenting on recent acquisitions of Japanese domestic pharmaceutical companies by companies from different industries, Eisai President Haruo Naito welcomed the M&A activities as inflow of new investments to energize the industry. As the Japanese government has shown support for innovation and strengthened assistance for pharmaceutical research and development, foreign investments will be flowing in as well. But Naito also cautioned about the industrial risks. Because pharmaceutical research and development is inevitably costly and the success of a company lies in its abilities to develop and market new drugs, Naito said, no matter what industries the new entries come from, a risk-taking attitude is a must. (Click here for more - Japanese language) "President Of Eisai Haruo Naito: Pharmaceutical Development Costly" - Sankai News (3/25/08)
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.